Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,518

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

Zacks Equity Research

Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.

Zacks Equity Research

Masimo (MASI) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.

Zacks Equity Research

Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.

Zacks Equity Research

Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.

Zacks Equity Research

Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat

by Zacks Equity Research

Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.

Zacks Equity Research

Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp

by Zacks Equity Research

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Zacks Equity Research

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.

Zacks Equity Research

Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

Zacks Equity Research

OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.

Zacks Equity Research

Repro Med Systems (KRMD) in Focus: Stock Moves 6.8% Higher

by Zacks Equity Research

Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.

Zacks Equity Research

Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag

by Zacks Equity Research

Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

Zacks Equity Research

DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

DaVita's (DVA) bottomline in Q4 declines year over year.

Zacks Equity Research

DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

Zacks Equity Research

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Zacks Equity Research

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.

Zacks Equity Research

Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

Zacks Equity Research

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Zacks Equity Research

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Zacks Equity Research

Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.